Centralize biolab oversight: GAO

A new government body should be formed to oversee the increasing number of high-containment laboratories that work with dangerous pathogens, according to a linkurl:Government Accountability Office (GAO) report;http://www.gao.gov/new.items/d09574.pdf released yesterday (September 21). Bacillus anthracis Image:P Paul Keim, linkurl:CDC EID,;http://www.cdc.gov/ncidod/EID/vol10no1/03-0238.htm via WikipediaIn the report, the GAO pointed out that such laboratories have proliferated since 2001; in 200

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
A new government body should be formed to oversee the increasing number of high-containment laboratories that work with dangerous pathogens, according to a linkurl:Government Accountability Office (GAO) report;http://www.gao.gov/new.items/d09574.pdf released yesterday (September 21).
Bacillus anthracis
Image:P Paul Keim, linkurl:CDC EID,;http://www.cdc.gov/ncidod/EID/vol10no1/03-0238.htm via Wikipedia
In the report, the GAO pointed out that such laboratories have proliferated since 2001; in 2008, there were 1,362 Biosafety Level 3 labs registered with the CDC, the report notes. But no single federal organization is in charge of overseeing this expansion and high-risk research. "While some federal agencies do have a mission to track a subset of BSL-3 and -4 laboratories that work with select agents and know the number of those laboratories, no single regulatory agency has specific responsibility for biosafety in all high-containment laboratories in the United States," the report states. There are also, the report notes, no laws that would help the government track such work, in contrast to the UK, for example, where new high-containment labs must receive approval or licensing from a central body. Centralizing oversight of high-containment research, the report concludes, would allow the development of a "strategic plan" regarding the number and location of such labs, as well as balance the risks and benefits of such research and determine the oversight needed. Some scientists, though, worry that more regulation is going to make their research more difficult. Already, said linkurl:Peter Palese,;http://www.mountsinai.org/Research/Centers%20Laboratories%20and%20Programs/Palese%20Laboratory a virologist at Mount Sinai School of Medicine in New York, responding to the report, restrictions for working with infectious agents are driving good scientists away. Stricter regulation won't prevent accidents, nor will they stand in the way of a "mad scientist" intent on doing evil, he added. "I don't think we need another [level of] oversight," Palese told The Scientist. "We are oversighted enough." Several highly publicized incidents in recent years have highlighted the risks involved with high containment laboratories. The GAO report discussed four such incidents -- including the linkurl:saga of Bruce Ivins,;http://www.the-scientist.com/blog/display/54907/ who the government claims perpetrated the 2001 anthrax attacks, and a series of safety snafus and failures to report accidents at linkurl:Texas A&M University,;http://www.the-scientist.com/blog/display/54350/ for which the university paid a $1 million fine -- and the implications they might have for centralized oversight.
**__Related stories:__***linkurl:Biosecurity rules under review;http://www.the-scientist.com/news/display/55821/
[9th July 2009]*linkurl:Pathogen labs lack security: GAO;http://www.the-scientist.com/blog/display/55093/
[16th October 2008]*linkurl:Biosafety lapses prompt govt review;http://www.the-scientist.com/news/display/53626/
[25th September 2007]*linkurl:The biosafety mess;http://www.the-scientist.com/article/display/15209/
[31th January 2005]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Alla Katsnelson

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Discover a serum-free way to produce dendritic cells and macrophages for cell therapy applications.

Optimizing In Vitro Production of Monocyte-Derived Dendritic Cells and Macrophages

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with Lipid Nanoparticles

Thermo Fisher Logo